Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor

Biochemical Pharmacology

Volumn 78, Issue 2, 2009, Pages 203-210

  Wu, Jia Jing ^a   Tang, Hung Kuan ^a   Yeh, Teng Kuang ^a   Chen, Chi Min ^b   Shy, Hrong Shing ^a   Chu, Yue Ru ^a   Chien, Chia Hui ^a   Tsai, Ting Yueh ^a   Huang, Yu Chen ^a   Huang, Yu Lin ^a   Huang, Chih Hsiang ^a   Tseng, Huan Yi ^a   Jiaang, Weir Torn ^a   Chao, Yu Sheng ^a   Chen, Xin ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

Author keywords

Dipeptidyl peptidase; DPP8; DPP9; Inhibitor; Pharmacokinetics; Toxicity

Indexed keywords

1 G 244; ALLOISOLEUCYL THIAZOLIDINE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; DIPEPTIDYL PEPTIDASE VIII IX INHIBITOR; ENZYME INHIBITOR; THIAZOLIDINE DERIVATIVE; THREOISOLEUCYL THIAZOLIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN TOXICITY; CELL MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY; TOXICITY TESTING;

ANIMALS; CELL LINE; DIPEPTIDASES; DIPEPTIDYL PEPTIDASES; FEMALE; HUMANS; MALE; PROTEASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 65649147246     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.032     Document Type: Article

References (34)

1. Rosenblum J.S., and Kozarich J.W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7 (2003) 496-504
2. Deacon C.F., Ahren B., and Holst J.J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Expert Opin Investig Drugs 13 (2004) 1091-1102
3. Pei Z. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Dev 11 (2008) 512-532
4. Deacon C.F. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs 16 (2007) 533-545
5. Deacon C.F., and Alogliptin. a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 9 (2008) 402-413
6. Rosenstock J., Sankoh S., and List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10 (2008) 376-386
7. Olsen C., and Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 299 (2002) 185-193
8. Ajami K., Abbott C.A., McCaughan G.W., and Gorrell M.D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 1679 (2004) 18-28
9. Abbott C.A., Yu D.M., Woollatt E., Sutherland G.R., McCaughan G.W., and Gorrell M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267 (2000) 6140-6150
10. Bjelke J.R., Christensen J., Nielsen P.F., Branner S., Kanstrup A.B., Wagtmann N., et al. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396 (2006) 391-399
11. Lee H.J., Chen Y.S., Chou C.Y., Chien C.H., Lin C.H., Chang G.G., et al. Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8. J Biol Chem 281 (2006) 38653-38662
12. Schade J., Stephan M., Schmiedl A., Wagner L., Niestroj A.J., Demuth H.U., et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 56 (2008) 147-155
13. Jiaang W.T., Chen Y.S., Hsu T., Wu S.H., Chien C.H., Chang C.N., et al. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett 15 (2005) 687-691
14. Van Goethem S., Van der Veken P., Dubois V., Soroka A., Lambeir A.M., Chen X., et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2. Isoindoline containing inhibitors. Bioorg Med Chem Lett 18 (2008) 4159-4162
15. Van der Veken P., De Meester I., Dubois V., Soroka A., Van Goethem S., Maes M.B., et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1. Identification of dipeptide derived leads. Bioorg Med Chem Lett 18 (2008) 4154-4158
16. Van der Veken P., Soroka A., Brandt I., Chen Y.S., Maes M.B., Lambeir A.M., et al. Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. J Med Chem 50 (2007) 5568-5570
17. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54 (2005) 2988-2994
18. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50 (2007) 2297-2300
19. Brandt I., Joossens J., Chen X., Maes M.B., Scharpe S., De Meester I., et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 70 (2005) 134-143
20. Burkey B.F., Hoffmann P.K., Hassiepen U., Trappe J., Juedes M., and Foley J.E. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab (2008)
21. Connolly B.A., Sanford D.G., Chiluwal A.K., Healey S.E., Peters D.E., Dimare M.T., et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 51 (2008) 6005-6013
22. Chen Y.S., Chien C.H., Goparaju C.M., Hsu J.T., Liang P.H., and Chen X. Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells. Protein Expr Purif 35 (2004) 142-146
23. Tang H.K., Tang H.Y., Hsu S.C., Chu Y.R., Chien C.H., Shu C.H., et al. Biochemical properties and expression profile of human prolyl dipeptidase DPP9. Arch Biochem Biophys (2009)
24. Chien C.H., Huang L.H., Chou C.Y., Chen Y.S., Han Y.S., Chang G.G., et al. One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem 279 (2004) 52338-52345
25. Chien C.H., Tsai C.H., Lin C.H., Chou C.Y., and Chen X. Identification of hydrophobic residues critical for DPP-IV dimerization. Biochemistry 45 (2006) 7006-7012
26. Aertgeerts K., Levin I., Shi L., Snell G.P., Jennings A., Prasad G.S., et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 280 (2005) 19441-19444
27. Leiting B., Pryor K.D., Wu J.K., Marsilio F., Patel R.A., Craik C.S., et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II. IV and VII. Biochem J 371 (2003) 525-532
28. Maes M.B., Lambeir A.M., Gilany K., Senten K., Van der Veken P., Leiting B., et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J 386 (2005) 315-324
29. Lu I.L., Lee S.J., Tsu H., Wu S.Y., Kao K.H., Chien C.H., et al. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg Med Chem Lett 15 (2005) 3271-3275
30. Tsai T.Y., Coumar M.S., Hsu T., Hsieh H.P., Chien C.H., Chen C.T., et al. Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 16 (2006) 3268-3272
31. Tsu H., Chen X., Chen C.T., Lee S.J., Chang C.N., Kao K.H., et al. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. J Med Chem 49 (2006) 373-380
32. Coumar M.S., Chang C.N., Chen C.T., Chen X., Chien C.H., Tsai T.Y., et al. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Bioorg Med Chem Lett 17 (2007) 1274-1279
33. Chou C.Y., Chien C.H., Han Y.S., Prebanda M.T., Hsieh H.P., Turk B., et al. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol 75 (2008) 1601-1609
34. Yao H.T., Wu Y.S., Chang Y.W., Hsieh H.P., Chen W.C., Lan S.J., et al. Biotransformation of 6-methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes. Drug Metab Dispos 35 (2007) 1042-1049